Publications by authors named "Miriam T Kastlmeier"

Introduction: Interstitial lung disease (ILD) is a heterogenous group of lung disorders where destruction and incomplete regeneration of the lung parenchyma often results in persistent architectural distortion of the pulmonary scaffold. Continuous mesenchyme-centered, disease-relevant signaling likely initiates and perpetuates the fibrotic remodeling process, specifically targeting the epithelial cell compartment, thereby destroying the gas exchange area.

Methods: With the aim of identifying functional mediators of the lung mesenchymal-epithelial crosstalk with potential as new targets for therapeutic strategies, we developed a 3D organoid co-culture model based on human induced pluripotent stem cell-derived alveolar epithelial type 2 cells that form alveolar organoids in presence of lung fibroblasts from fibrotic-ILD patients, in our study referring to cases of pulmonary fibrosis, as well as control cell line (IMR-90).

View Article and Find Full Text PDF

Lung epithelial organoids for the hazard assessment of inhaled nanomaterials offer a promising improvement to in vitro culture systems used so far. Organoids grow in three-dimensional (3D) spheres and can be derived from either induced pluripotent stem cells (iPSC) or primary lung tissue stem cells from either human or mouse. In this perspective we will highlight advantages and disadvantages of traditional culture systems frequently used for testing nanomaterials and compare them to lung epithelial organoids.

View Article and Find Full Text PDF
Article Synopsis
  • STAT3-hyper IgE syndrome (STAT3-HIES) is a genetic immune disorder causing lung issues and other symptoms.
  • CRISPR-Cas9 technology has been utilized to correct a specific mutation (p.R382W) associated with this condition in patient-derived fibroblasts and iPSCs, achieving about 29%-30% correction efficiency without harmful off-target effects.
  • The treated cells demonstrated improved STAT3 signaling and maintained their ability to develop into functional alveolar organoids, suggesting ABE-based gene editing could be a promising treatment for STAT3-HIES.
View Article and Find Full Text PDF